» Articles » PMID: 39230007

The Acute Kidney Intervention and Pharmacotherapy (AKIP) List: Standardized List of Medications That Are Renally Eliminated and Nephrotoxic in the Acutely Ill

Abstract

The objective of this project was to develop a standardized list of renally eliminated and potentially nephrotoxic drugs that will help inform initiatives to improve medication safety. Several available lists of medications from the published literature including original research articles and reviews, and from regulatory agencies, tertiary references, and clinical decision support systems were compiled, consolidated, and compared. Only systemically administered medications were included. Medication combinations were included if at least 1 active ingredient was considered renally dosed or potentially nephrotoxic. The medication list was reviewed for completeness and clinical appropriateness by a multidisciplinary team of individuals with expertise in critical care, nephrology, and pharmacy. An initial list of renally dosed and nephrotoxic drugs was created. After reconciliation and consensus from clinical experts, a standardized list of 681 drugs is proposed. The proposed evidence-based standardized list of renally dosed and potentially nephrotoxic drugs will be useful to harmonize epidemiologic and medication quality improvement studies. In addition, the list can be used for clinical purposes with surveillance in nephrotoxin stewardship programs. We suggest an iterative re-evaluation of the list with emerging literature and new medications on an approximately annual basis.

Citing Articles

Challenges in renally eliminated medication use: Evaluating cystatin C and serum creatinine eGFR discordance.

Hernandez B, Wieruszewski P, Barreto J, Cole K, Damani S, Kane-Gill S Pharmacotherapy. 2024; 44(12):898-906.

PMID: 39601345 PMC: 11693467. DOI: 10.1002/phar.4627.

References
1.
Hall R, Blumenthal J, Doerfler R, Chen J, Diamantidis C, Jaar B . Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021; 78(6):837-845.e1. PMC: 8608689. DOI: 10.1053/j.ajkd.2021.03.019. View

2.
Vogel E, Billups S, Herner S, Delate T . Renal Drug Dosing. Effectiveness of Outpatient Pharmacist-Based vs. Prescriber-Based Clinical Decision Support Systems. Appl Clin Inform. 2016; 7(3):731-44. PMC: 5052546. DOI: 10.4338/ACI-2016-01-RA-0010. View

3.
Cox Z, McCoy A, Matheny M, Bhave G, Peterson N, Siew E . Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013; 8(7):1070-8. PMC: 3700703. DOI: 10.2215/CJN.11921112. View

4.
Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

5.
Secora A, Alexander G, Ballew S, Coresh J, Grams M . Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults. Drugs Aging. 2018; 35(8):735-750. PMC: 6093216. DOI: 10.1007/s40266-018-0563-1. View